<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> use has been associated with decreased <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk and mortality </plain></SENT>
<SENT sid="1" pm="."><plain>However, the effects of <z:chebi fb="0" ids="6801">metformin</z:chebi> on clinical outcomes of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) are not defined </plain></SENT>
<SENT sid="2" pm="."><plain>This study aimed to evaluate the association between <z:chebi fb="0" ids="6801">metformin</z:chebi> use and mortality of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> in diabetic patients </plain></SENT>
<SENT sid="3" pm="."><plain>We identified 595 patients who were diagnosed both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> and <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were compared by two groups; 258 diabetic patients taking <z:chebi fb="0" ids="6801">metformin</z:chebi> and 337 diabetic patients not taking <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Patient's demographics, clinical characteristics, overall mortality and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-specific mortality were analyzed </plain></SENT>
<SENT sid="6" pm="."><plain>After a median follow-up of 41 months, there were 71 total <z:hpo ids='HP_0011420'>deaths</z:hpo> (27.5%) and 55 CRC-specific <z:hpo ids='HP_0011420'>deaths</z:hpo> (21.3%) among 258 patients who used <z:chebi fb="0" ids="6801">metformin</z:chebi>, compared with 136 total <z:hpo ids='HP_0011420'>deaths</z:hpo> (40.4%) and 104 CRC-specific <z:hpo ids='HP_0011420'>deaths</z:hpo> (30.9%) among 337 patients who did not use <z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> use was associated with decreased overall mortality (p = 0.018) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-specific mortality (p = 0.042) by univariate analysis </plain></SENT>
<SENT sid="8" pm="."><plain>After adjustment for clinically relevant factors, <z:chebi fb="0" ids="6801">metformin</z:chebi> use showed lower risk of overall mortality (HR, 0.66; 95% CI 0.476-0.923; p = 0.015) and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-specific mortality (HR, 0.66; 95% CI 0.45-0.975; p = 0.037) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> use in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients with <z:mp ids='MP_0002055'>diabetes</z:mp> is associated with lower risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>-specific and overall mortality </plain></SENT>
</text></document>